Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristics of AS patients in a Korean population. Methods: Sixty-eight Korean patients with AS participated in the phase 3, multicenter, randomized, placebo-controlled, double-blind trial (GO-RAISE) which has previously been described. Baseline modified stoke AS spine score (mSASSS) and change in mSASSS from baseline (ΔmSASSS) until week 208 were analyzed in the Korean patients enrolled in the GO-RAISE study. Results: Although Korean patients had lower baseline mSASSS compared to non-Korean patients and received active management, radiographic progression was not prevented. Korean patients who did not undergo radiographic progression of spinal lesions of AS were younger and had shorter symptomatic duration, lower Bath AS functional and metrology indices, better chest expansion, and lower baseline mSASSS. The baseline mSASSS and ΔmSASSS were positively correlated in Korean AS patients (p < 0.001). Radiographic progression was more prevalent (80.0%) when baseline mSASSS > 10 and less common (13.0%) with baseline mSASSS = 0. Conclusions: In Korean AS patients, radiographic progression of the spine after 4 years was predicted effectively by the initial severity of the spinal lesion(s) in patients treated with golimumab.
Abstract
Background/Aims: For patients with ankylosing spondylitis (AS), golimumab has consistent efficacy in controlling disease activity over 5 years but its benefit in preventing radiographic progression was less clear at 4 years. To predict radiographic progression, we analyzed the baseline characteristics of AS patients in a Korean population. Methods: Sixty-eight Korean patients with AS participated in the phase 3, multicenter, randomized, placebo-controlled, double-blind trial (GO-RAISE) which has previously been described. Baseline modified stoke AS spine score (mSASSS) and change in mSASSS from baseline (ΔmSASSS) until week 208 were analyzed in the Korean patients enrolled in the GO-RAISE study. Results: Although Korean patients had lower baseline mSASSS compared to non-Korean patients and received active management, radiographic progression was not prevented. Korean patients who did not undergo radiographic progression of spinal lesions of AS were younger and had shorter symptomatic duration, lower Bath AS functional and metrology indices, better chest expansion, and lower baseline mSASSS. The baseline mSASSS and ΔmSASSS were positively correlated in Korean AS patients (p < 0.001). Radiographic progression was more prevalent (80.0%) when baseline mSASSS > 10 and less common (13.0%) with baseline mSASSS = 0. Conclusions: In Korean AS patients, radiographic progression of the spine after 4 years was predicted effectively by the initial severity of the spinal lesion(s) in patients treated with golimumab.
참고문헌 (18)
- Landewe R, "Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine", Ann Rheum Dis, 68, pp.863~867 (2009)[DOI]
- Creemers MC, "Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system", Ann Rheum Dis, 64, pp.127~129 (2005)[DOI]
- Baraliakos X, "Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab", Ann Rheum Dis, 64, pp.1462~1466 (2005)[DOI]
- Baraliakos X, "Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab", Rheumatology (Oxford), 46, pp.1450~1453 (2007)[DOI]
- van der Heijde D, "Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept", Arthritis Rheum, 58, pp.1324~1331 (2008)[DOI]
- van der Heijde D, "Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years", Arthritis Res Ther, 11, pp.R127~ (2009)[DOI]
- Braun J, "The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial", Ann Rheum Dis, 73, pp.1107~1113 (2014)[DOI]
- Deodhar A, "Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study", Ann Rheum Dis, 74, pp.757~761 (2015)[DOI]
- Baek HJ, "Clinical features of adultonset ankylosing spondylitis in Korean patients: patients with peripheral joint disease (PJD) have less severe spinal disease course than those without PJD", Rheumatology (Oxford), 43, pp.1526~1531 (2004)[DOI]
- Kim TJ, "The presence of peripheral arthritis delays spinal radiographic progression in ankylosing spondylitis: Observation Study of the Korean Spondyloarthropathy Registry", Rheumatology (Oxford), 53, pp.1404~1408 (2014)[DOI]
- Maksymowych WP, "Spondyloarthritis in 2012: advances in pathogenesis through animal models and imaging", Nat Rev Rheumatol, 9, pp.72~74 (2013)[DOI]
- Maksymowych WP, "Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification", Ann Rheum Dis, 72, pp.23~28 (2013)[DOI]
- Baraliakos X, "Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes", Ann Rheum Dis, 66, pp.910~915 (2007)[DOI]
- Haroon N, "The impact of tumor necrosis factor <TEX>${\alpha}$<", TEX> inhibitors on radiographic progression in ankylosing spondylitis, 2013, pp.65, 2645~2654
- Lee SH, "Human leukocyte antigen-B*2705 is the predominant subtype in the Korean population with ankylosing spondylitis, unlike in other Asians", Rheumatol Int, 29, pp.43~46 (2008)[DOI]
- Kim TJ, "Clinical spectrum of ankylosing spondylitis in Korea", Joint Bone Spine, 77, pp.235~240 (2010)[DOI]
- Ji-HyunLee, "Higher Prevalence of Peripheral Arthritis Among Ankylosing Spondylitis Patients", Journal of Korean Medical Science, 17(5), pp.669~673 (2002), 대한의학회
- Heuft-Dorenbosch L, "The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index", Arthritis Rheum, 51, pp.154~159 (2004)[DOI]